This trial is completed!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
2Find
3Review
4Get in touch
More info
You can access this
clinical trial
if you have
Infections, Meningococcal
and you are
between 18 and 45
years old
1
This is an early phase trial to determine
the dosage and safety of the new treatment.
Show me locations

The purpose

Dosage-Escalation Study to Evaluate the Safety and Immunogenicity of an Aluminium Hydroxide/LHD153R Adjuvanted Meningococcal C-CRM197 Conjugate Vaccine in Healthy Adults (18-45 years of age).

Provided treatments

  • Biological: Investigational MenC-CRM adjuavnted with 12.5 ug of LHD153R
  • Biological: Investigational MenC-CRM adjuavnted with 25 ug of LHD153R
  • Biological: Investigational MenC-CRM adjuavnted with 50 ug of LHD153R
  • Biological: Investigational MenC-CRM adjuavnted with 100 ug of LHD153R
  • Biological: Meningococcal C-CRM Conjugate Vaccine (MenC-CRM)

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT02639351. The sponsor of the trial is GlaxoSmithKline and it is looking for 80 volunteers for the current phase.
Official trial title:
A Phase 1, Randomized, Observer-Blind, Dosage-Escalation Study to Evaluate the Safety and Immunogenicity of an Aluminium Hydroxide/LHD153R Adjuvanted Meningococcal C-CRM197 Conjugate Vaccine Compared to Aluminium Hydroxide Adjuvanted Meningococcal C-CRM197 Conjugate Vaccine in Healthy Adults (18-45 Years of Age).